pegcetacoplan: Clinical Trials

11 trials of pegcetacoplan, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 4 recruiting, 2 terminated. 11 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 211Completed 5, Recruiting 4, Terminated 2
Phase 12Recruiting 1, Terminated 1

Follow pegcetacoplan: new trials by email Literature Review of pegcetacoplan trials Research Report on pegcetacoplan

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Phase 1 / Phase 2RecruitingRoswell Park Cancer Institute352026-02-162026-08-19
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio
APL-3007, pegcetacoplan (APL-2), Placebo, Syfovre - Geographic Atrophy Secondary to Age-related Macular Degeneration
Phase 2RecruitingApellis Pharmaceuticals, Inc.2402025-06-232026-06-24
A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
BI 771716, Pegcetacoplan, Sham comparator to BI 771716 - Macular Degeneration, Age-related, Geographic Atrophy
Phase 2CompletedBoehringer Ingelheim2022025-01-062026-11-12
APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion
Bevacizumab, Biopsy, Biospecimen Collection - Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma
Phase 2RecruitingRoswell Park Cancer Institute602023-04-272026-03-23
A Study of Pegcetacoplan for Patients With Transplant-associated Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplantation
Pegcetacoplan - Transplant-Associated Thrombotic Microangiopathy
Phase 2CompletedSwedish Orphan Biovitrum122022-02-012025-11-28
Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN
Pegcetacoplan - C3G, IC-MPGN
Phase 2CompletedApellis Pharmaceuticals, Inc.132021-09-072026-04-21
A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pegcetacoplan - Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Hemoglobinuria
Phase 2RecruitingApellis Pharmaceuticals, Inc.122021-02-042026-06-26
MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)
Pegcetacoplan (APL-2), Placebo - Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Phase 2TerminatedApellis Pharmaceuticals, Inc.2492020-09-302025-04-24
A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNH
Pegcetacoplan - PNH
Phase 2CompletedApellis Pharmaceuticals, Inc.42018-08-162020-12-22
Pegcetacoplan (APL-2) in Neovascular AMD
Pegcetacoplan - Neovascular Age-related Macular Degeneration
Phase 1 / Phase 2TerminatedApellis Pharmaceuticals, Inc.172018-02-142020-09-16
Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy
Pegcetacoplan, Sham Procedure - Geographic Atrophy
Phase 2CompletedApellis Pharmaceuticals, Inc.2462015-09-242020-10-06

Conditions studied

Geographic Atrophy (2)  ·  Hemoglobinuria, Paroxysmal (2)  ·  Amyotrophic Lateral Sclerosis (1)  ·  Anemia (1)  ·  Anemia, Hemolytic (1)  ·  Fallopian Tube Neoplasms (1)  ·  Glomerulonephritis, Membranoproliferative (1)  ·  Hematologic Diseases (1)  ·  Hemoglobinuria (1)  ·  Hemolysis (1)  ·  Macular Degeneration (1)  ·  Motor Neuron Disease (1)  ·  Ovarian Neoplasms (1)  ·  Pancreatic Neoplasms (1)

Sponsors

Apellis Pharmaceuticals, Inc. (7)  ·  Roswell Park Cancer Institute (2)  ·  Boehringer Ingelheim (1)  ·  Swedish Orphan Biovitrum (1)

Countries

United States (10)  ·  France (4)  ·  Spain (4)  ·  Australia (3)  ·  Italy (3)  ·  Netherlands (3)  ·  United Kingdom (3)  ·  Czechia (2)  ·  Serbia (2)  ·  Argentina (1)  ·  Austria (1)  ·  Belgium (1)  ·  Brazil (1)  ·  Bulgaria (1)  ·  Germany (1)

Top investigators

Federico Grossi, MD, PhD (2)  ·  Christos Fountzilas (1)  ·  Emese Zsiros (1)  ·  Federico Grossi, MD PhD (1)

Results publications

PMID 35113137, PMID 35860926, PMID 35869170, PMID 35948209, PMID 36284220, PMID 37314061, PMID 37715860, PMID 38752918, PMID 39522752

NIH funding

2023 (1), R01CA267690 (1)